medigraphic.com
ISSN 0188-2198 (Print)

2003, Number 1

<< Back Next >>

Rev Mex Cardiol 2003; 14 (1)

Favorable changes in the hemodynamic Doppler-derived parameters of aortic flow with estrogenic therapy in menopausal women

Contreras ZM, Contreras ZJI, Moragrega AJL

Language: Spanish
References: 32
Page: 8-15
PDF size: 82.78 Kb.


ABSTRACT

A positive inotropic effect of estrogens has been shown in some papers, and some biochemical mechanisms have been suggested. This is expected because estrogens and digitalis have similar chemical structure. The object of this study was to observe the effects of estrogens on Doppler-derived parameters of aortic flow in menopausal women, in comparison with a group receiving placebo. The active treatment group was 24 menopausal women that received natural estrogens (Premarin) 0.625 mg for eight weeks, and 19 healthy women without medication received placebo as the control group for the same period. Menopause was present for at least one year. Ejection time increased 38.0 msec (p=0.003) in the estrogen group and 16.9 msec (p NS) in the control group. Medium Velocity changes were 0.03 msec (p=0.038) and 0.01 msec (p NS) respectively. There was a tendency in favor for of active treatment group in Peak Aortic Flow Velocity, Flow Velocity Integral and Acceleration Mean Time, but did not reach statistics significance. This study is in agreement with the previous published data, and shows an increment in left ventricular performance with estrogens alone. We suggest that the endogenous “digoxin-like” substance found in high estrogens states like normal pregnancy, pre-eclampsia, is the estrogen, its precursors or metabolites. This findings give additional support to the use of estrogens in menopausal women.


REFERENCES

  1. Bush TL, Barret-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow up study. Circulation 1987; 75: 1102-1109.

  2. Stampfer MJ, Colditz GA, Wuillet WC et al. Postmenopausal estrogen therapy and cardiovascular disease: ten years follow-up from the Nurses’ Health Study. N Engl J Med 1991; 325: 756-762.

  3. Sullivan JM, Vander ZR, Lemp GF et al. Estrogen replacement and coronary artery disease: effect in survival in postmenopausal women. Arch Intern Med 1990; 150: 2557-2562.

  4. Henderson BE, Pagannini HA, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75-77.

  5. Pines A, Fisman EZ, Ayalon D, Drory Y, Aberbuch M, Levo Y. Long-term effects of hormone replacement therapy on Doppler-derived parameters of aortic flow post-menopausal women. Chest 1992; 102: 1496-1498.

  6. Samaan SA, Crawford MH. Estrogen and cardiovascular function after menopause. J Am Coll Cardiol 1995; 26: 1403-1410.

  7. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992; 20(2): 452-457.

  8. Hart MV, Hosenpud JD, Hohimer R, Morton MJ. Hemodynamics during pregnancy and sex steroid administration in guinea pigs. Am J Physiol 1985; 249: R179-185.

  9. Veille JC, Morton MJ, Burry K, Nemeth M, Speroff L. Estradiol and hemodynamics during ovulation induction. J Clin Endocrinol Metab 1986; 63: 721-724.

  10. Lehtovirta P. Haemodynamics effects of combinated estrogen-progestogen oral contraceptives. Br J Obstet Ginaecol 1974; 81: 517-25.

  11. Scheuer J, Malhotra A, Schaible TF, Capasso J. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 1987; 61: 12-19.

  12. Pines A, Fisman EZ, Drory Y, Levo Y, Shemesh J, Ben-Ari E, Ayalon D. Menopause-induced changes in Doppler parameters of aortic flow in healthy women. Am J Cardiol 1992; 69: 1104-1106.

  13. Pines A, Fisman EZ, Levo Y et al. The effects of hormone therapy in normal postmenopausal women: Measurements of Doppler-derived parameters of aortic flow. Am J Obstet Gynecol 1991; 164: 806-812.

  14. Moe GK, Farah AE. Digital y glucósidos afines cardiacos. Goodman LS, Gilman A. Bases farmacológicas de la terapéutica. Quinta Edición. México, D.F. Nueva Editorial Interamericana, 1978: 551-563.

  15. Murad F, Gilman AG. Estrógenos y progestinas. Goodman LS, Gilman A. Bases farmacológicas de la terapéutica. Quinta Edición. México, D.F. Nueva Editorial Interamericana, 1978: 1198-1221.

  16. Rosano GMC, Rillo M, Leonardo F, Papone C, Russo T, Sheiban I, Chierchia SL. XIIIth World Congress of Cardiology, abstract: 1152. Suplement to J Am Coll Cardiol, Vol 31 Num 5 (Supplement C). 1998.

  17. Buonanno C, Arbustini E, Rossi L et al. Left ventricular function in men and women: Another difference between sexes. Eur Heart J 1982; 3: 525-528.

  18. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985; 312: 277.

  19. Echeverria HH, Bilsker MS, Myerburg RJ et al. Congestive heart failure: Echocardiographic insights. Am J Med 1983; 75: 750-756.

  20. Gruber KA, Whitaker JM, Buckalew VM. Endogenous digitalis-like substance in the plasma of volumen expanded dogs. Nature (London) 1980; 287: 743-745.

  21. Castañeda-Hernández G, Godfraind T. Effect of high sodium intake on tissue distribution of endogenous digitalis-like material in the rat. Clin Sci 1984; 66: 225-228.

  22. Steiner E, Person S, Wester PO. Positive inotropic drugs-digitalis. Symposium on the endocrinology of cardiac failure. Stockholm, April 25-26, 1985. Sponsored by The Swedish Society of Cardiology. Also published as supplementum 707 to Acta Medica Scandinavica. 1986: 63-64.

  23. Delva P, Capra C, Degan M, Minuz P, Covi M G, Milan L, Steele A, Lechi A. High plasma levels of a oubain-like factor in normal pregnancy and in pre-eclampsia. Eur J Clin Invest 1989; 19: 95-100.

  24. Logoglu G, Erdogan S, Ozgunen FT, Dogan A, Ozgunen T, Kadayifci O. Endogenous digoxin-immunoreactive substance in normal and preeclamptic pregnancies. Int J Gynaecol Obstet 1993; 43(2): 137-143.

  25. Yapar EG, Ayhan A. The influence of tocolytic therapy on serum digoxin-like immunoreactive substance concentration. Gynecol Obstet Invest 1994; 37(1): 10-13.

  26. Di Grande A, Boura AL, Read MA, Malatino LS, Walters WA. Release of a substance from the human placenta having digoxin-like immunoreactivity. Clin Exp Pharmacol Physiol 1993; 20(9): 603-607.

  27. Yun WS, Ho CS, Panesar NS, Swaminathan R. The contribution of steroids to digoxin-like immunoreactivity in cord blood. Ann Clin Biochem 1992; 29(Pt 3): 337-342.

  28. Lucena M, Andrade RJ, Fralle JM, Alcantara R, González-Correa JA, De La Cuesta FS. Endogenous digoxin-like substance in liver failure. Int J Clin Pharmacol Ther 1994; 32(10): 567-569.

  29. Kuhl H. Hormonale Kontraception and substitutions therapie: Die Bedeutung des Gestagens fur kardiovasculare Erkran kungen. [Hormonal contraception and substitution therapy: the importance of progestogen for cardiovascular diseases]. Gebursthilfe- Frauenheilkd 1992; 52(11): 653-662.

  30. Gardin J, Dabestani A, Matin K, Allfie A, Russell D, Henry L. Reproducibility of Doppler aortic blood flow measurements: studies on intraobserver, interobsever and day-to day variability in normal subjects. Am J Cardiol 1984; 54: 1092-1098.

  31. Stumpf WE, Sar M, Aumuller G. The heart: a target organ for estradiol. Science 1977; 193: 319-320.

  32. Braquet P, Senn N, Robin J-P, Esanu A, Garay RP. Endogenous Lignans- a potential endogenous digitalis. J Hypertens Suppl 1986; 4: S161-4.




2020     |     www.medigraphic.com